Logo

BRKR

Bruker Corporation

BRKR

Bruker Corporation • NASDAQ
$48.81 ▼ -0.45% (-0.22)
Market Cap $7.40 B
52w High $64.64
52w Low $28.53
Dividend Yield 0.20%
P/E -305.06
Volume 1.05M
Outstanding Shares 151.70M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $860.5M ▲ $319.3M ▼ $-59.6M ▼ -6.926% ▼ $-0.411 ▼ $3.1M ▼
Q2-2025 $797.4M ▼ $346M ▼ $7.6M ▼ 0.953% ▼ $0.05 ▼ $72.3M ▼
Q1-2025 $801.4M ▼ $359.4M ▼ $17.4M ▲ 2.171% ▲ $0.11 ▲ $88.6M ▼
Q4-2024 $979.6M ▲ $421.2M ▲ $13.7M ▼ 1.399% ▼ $0.09 ▼ $124.6M ▲
Q3-2024 $864.4M $350.7M $40.9M 4.732% $0.27 $117.9M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $295M ▲ $6.435B ▲ $3.942B ▼ $2.432B ▲
Q2-2025 $92M ▼ $6.34B ▲ $4.473B ▲ $1.804B ▼
Q1-2025 $184.2M ▲ $5.933B ▲ $4.082B ▲ $1.817B ▲
Q4-2024 $183.4M ▲ $5.807B ▼ $3.991B ▼ $1.781B ▼
Q3-2024 $148.1M $6.113B $4.27B $1.807B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-59.6M ▼ $-33.2M ▲ $-23.8M ▲ $258.4M ▲ $201.1M ▲ $-54.1M ▲
Q2-2025 $4.2M ▼ $-127.5M ▼ $-91.1M ▼ $95.5M ▲ $-91.5M ▼ $-148.8M ▼
Q1-2025 $16.8M ▲ $65M ▼ $-26.1M ▲ $-51.2M ▲ $1M ▼ $39M ▼
Q4-2024 $13.9M ▼ $190M ▲ $-60.6M ▲ $-75M ▼ $35M ▲ $153.3M ▲
Q3-2024 $40.3M $38.4M $-67.6M $-2.7M $-21.5M $5.8M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $810.00M ▲$640.00M ▼$630.00M ▼$690.00M ▲
Product and Service Other
Product and Service Other
 $170.00M ▲$160.00M ▼$160.00M ▲$170.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Bruker’s sales have climbed steadily over the past several years, showing that demand for its instruments and solutions is growing. However, profits have been much more uneven: margins improved for a while, then compressed noticeably in the most recent year despite higher revenue. This suggests rising costs, integration expenses, or other one‑time charges are weighing on earnings, and that converting strong sales growth into consistent bottom‑line performance remains a key challenge.

Balance Sheet

Balance Sheet The company’s asset base has expanded meaningfully, likely reflecting acquisitions and continued investment in its technology platforms. At the same time, debt has risen and cash on hand has come down, which means the balance sheet is now more leveraged than in prior years, even though shareholder equity has also grown. Overall, Bruker appears stronger in scale but with less liquidity and more reliance on borrowing, which slightly reduces financial flexibility if conditions turn weaker.

Cash Flow

Cash Flow Bruker consistently generates positive cash from its operations and retains positive free cash flow after investment in new equipment and facilities. That said, cash generation dipped in the most recent year, even as revenue grew, which points to pressure from lower margins or working capital needs. Capital spending looks disciplined rather than aggressive, but there is not a large cash cushion, so ongoing attention to maintaining or improving free cash flow will be important to support debt and continued investment.

Competitive Edge

Competitive Edge Bruker holds a strong and specialized position in premium scientific instruments, particularly in nuclear magnetic resonance, advanced mass spectrometry, and microbiology identification systems. Its brand, deep relationships with top research labs, and high switching costs from complex installed systems create meaningful barriers for rivals. However, it still competes against very large life‑science and instrument players, so continued differentiation in performance, data quality, and workflow integration is crucial to defend and expand its niche leadership.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Bruker’s strategy: it invests heavily in research and development and has a long track record of leading technologies in NMR, mass spectrometry, and microscopy. Recent moves into proteomics, metabolomics, spatial biology, and single‑cell analysis, supported by targeted acquisitions, show a push into faster‑growing “omics” and clinical applications. This innovation engine and strong patent portfolio support its moat, but they also bring execution risks around integrating acquisitions, aligning software and hardware platforms, and turning new technologies into scalable, profitable product lines.

Summary

Bruker combines strong top‑line growth and a clear technological edge with more mixed recent profitability and a somewhat more stretched balance sheet. The business is evolving from a specialized instrument supplier toward a broader life‑science and applied‑markets solutions provider, anchored by high‑end analytical tools and data‑rich workflows. The main opportunities lie in leveraging its scientific leadership into faster‑growing application areas, while the main watch points are restoring margin momentum, sustaining solid cash generation, and smoothly integrating new acquisitions without overburdening the balance sheet.

NEWS

November 24, 2025 · 9:00 AM UTC

Indaba Capital Announces Sale of AST Revolution to Bruker

Read more

November 4, 2025 · 4:01 PM UTC

Bruker Announces Quarterly Common Stock Dividend and Preferred Stock Dividend

Read more

November 3, 2025 · 7:00 AM UTC

Bruker Reports Third Quarter 2025 Financial Results

Read more

October 22, 2025 · 4:05 PM UTC

Bruker Announces Date and Time of Third Quarter 2025 Earnings Release and Webcast

Read more

October 3, 2025 · 7:00 AM UTC

Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University

Read more